Anti-acne positioning is a regulatory boundary, not just a marketing choice. In the United States, a skin-care product can be a cosmetic, a drug, or both. For private-label brands, the product’s intended use—communicated through its label, website, marketplaces, social posts, and other promotional materials—drives the analysis. This guide explains the practical distinction and the controls a brand should establish before offering an anti-acne product in the U.S.
This article is general educational information, not legal advice. Product classification, labeling, formula, and launch decisions should be reviewed against current law and with qualified regulatory counsel.
Why “anti-acne cosmetic” is a high-risk phrase
Under the Federal Food, Drug, and Cosmetic Act, cosmetics are generally products intended to cleanse, beautify, promote attractiveness, or alter appearance. Drugs include products intended to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or function of the body. FDA specifically identifies acne treatments as drugs. A cleanser that is also promoted as an acne treatment may therefore be both a cosmetic and a drug, and must meet the applicable requirements for each category.
The same bottle, ingredient list, and packaging can create a different regulatory outcome when the claims change. “Cleanses oily-looking skin” and “helps skin feel refreshed” describe cosmetic-type appearance or cleansing benefits. “Treats acne,” “clears pimples,” “prevents breakouts,” or “unclogs pores to reduce blackheads” may communicate drug intended use. Claims should never be evaluated in isolation: imagery, product name, influencer scripts, search ads, before-and-after material, retail filters, and FAQs can all matter.
Start with intended use, then choose the route
| Commercial objective | Typical regulatory signal | Practical launch implication |
|---|---|---|
| Cleanse, beautify, moisturize, or improve the look or feel of skin | Cosmetic positioning | Use truthful, non-misleading cosmetic claims and meet applicable cosmetic safety and labeling responsibilities. |
| Treat acne, reduce acne blemishes, prevent acne, or affect a physiological function | Drug positioning | Assess the applicable drug framework, including OTC-monograph conditions where relevant; do not treat this as an ordinary cosmetic launch. |
| Cleanse or beautify while also treating acne | Combination cosmetic-drug positioning | Plan for requirements applicable to both product categories; do not rely on cosmetic compliance alone. |
What FDA’s OTC acne monograph means in practice
FDA’s OTC Monograph M006 addresses topical acne drug products for OTC human use. It identifies active-ingredient and labeling conditions for products within the monograph. Examples of listed acne active ingredients include benzoyl peroxide at 2.5–10%, salicylic acid at 0.5–2%, and sulfur at 3–10%, subject to the monograph’s complete conditions and permitted combinations.
That does not mean a brand can select an ingredient and make any acne claim it wants. The finished product, concentration, dosage form, active-ingredient presentation, Drug Facts labeling, warnings, directions, manufacturing controls, and promotional claims need a product-specific assessment. If a concept does not fit an applicable OTC-monograph pathway, a different regulatory path may be required. Do not imply that a product is “FDA approved” simply because a facility is registered, a product is listed, an ingredient is common, or a monograph is relevant.
Build a claim-control system before creative production
A reliable launch process reviews claims before they reach packaging or campaigns. Use a central claim register that identifies the exact claim, its channel, the intended regulatory category, the supporting evidence, owner, approved wording, and prohibited variations. The review should cover more than the principal display panel.
- Packaging and inserts: product name, front-label statements, directions, warnings, ingredient declarations, and QR-linked pages.
- Digital commerce: product-detail pages, search keywords, retailer bullets, subscription copy, and FAQs.
- Marketing: paid ads, email, social posts, creator briefs, testimonials, and before-and-after assets.
- Customer service: approved response scripts so post-sale messages do not create unauthorized intended-use claims.
For a product intended to remain a cosmetic, avoid disease-treatment language and avoid promising changes to skin physiology. “For acne-prone skin” can also require careful context; the safer approach is not a universal phrase list but a documented review of the complete presentation and the market in which the claim will appear.
MoCRA does not turn a drug into a cosmetic
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) added important cosmetic obligations, including facility-registration and product-listing provisions, serious-adverse-event reporting, and safety-substantiation expectations. FDA explains that a responsible person is the manufacturer, packer, or distributor named on the cosmetic label. Certain small-business exemptions may apply, subject to limits.
However, MoCRA is not a substitute for drug compliance. If the intended use makes a product a drug or a combination product, cosmetic registration or listing cannot cure a drug-classification issue. Teams should decide the category first, then map the appropriate obligations for that category.
Launch checklist for a private-label anti-acne concept
- Freeze the intended use. Record exactly what the product is and is not intended to do.
- Review formula and active status. Identify whether an active ingredient and proposed indication point to an OTC drug pathway.
- Audit all claims. Include packaging, website, marketplaces, paid media, creator content, customer-support scripts, and translations.
- Validate labeling. Ensure the label format and statements match the determined category; drug products require their own labeling analysis.
- Confirm quality and safety evidence. Keep technical documentation, supplier records, specifications, stability or microbiological support where applicable, and a complaint process proportionate to the product.
- Assign accountability. Name an internal owner for regulatory change control, adverse-event escalation, and ongoing claim monitoring.
- Run a final channel check. Review the live product page and every launch asset before publication, not only the artwork proof.
Launch documentation checklist
Keep the product file organized before packaging or retail content is finalized. The precise documents depend on the product category and commercial route, but a disciplined set of records supports a defensible review.
| Information set | Why it matters | Typical source |
|---|---|---|
| Approved claims register and substantiation file | Connects each label, marketplace, and campaign statement with the evidence and regulatory route supporting it. | Brand regulatory and marketing review records |
| Final label artwork and any Drug Facts elements where applicable | Allows a complete intended-use and labeling check before printing or listing. | Packaging artwork control and regulatory file |
| Formula, ingredient specifications, and active-ingredient assessment | Supports classification and confirms whether an OTC drug pathway needs separate evaluation. | Manufacturer technical file and qualified regulatory review |
| Batch traceability, product specifications, and complaint escalation process | Supports quality control and prompt investigation of market feedback or safety issues. | Manufacturer quality records and brand post-market process |
Manufacturer and brand owner responsibilities
For a private-label anti-acne project, clear ownership helps keep formula, evidence, labeling, and claims aligned. The allocation below is a practical project-control model; final legal responsibilities depend on the product route and commercial arrangements.
| Manufacturer can provide | Brand owner should control |
|---|---|
| Formula information, ingredient specifications, batch documentation, and relevant stability or microbiological support. | Final intended use, target-market route, claims strategy, commercial label, and launch approval. |
| Technical input on packaging compatibility, production controls, and product specifications. | Review of Drug Facts or cosmetic label elements where applicable, channel copy, retailer content, and creator instructions. |
| Support for samples and quality records appropriate to the agreed manufacturing scope. | Confirmation that the finished product and all communications meet current U.S. requirements with qualified regulatory advice. |
Frequently asked questions
Can a cosmetic say it “treats acne”?
FDA identifies acne treatments as drugs. A cosmetic marketed with a disease-treatment claim may be regulated as a drug, or as both a cosmetic and a drug, depending on its intended use and complete presentation.
Does “FDA registered” mean an anti-acne product is FDA approved?
No. FDA states that cosmetics and cosmetic ingredients generally do not require FDA approval before market, except for color additives in specified circumstances. FDA also warns that cosmetics should not be labeled or advertised in a way that suggests FDA approval.
Are benzoyl peroxide and salicylic acid automatically compliant?
No. FDA’s OTC acne monograph contains conditions for topical OTC acne drug products. A finished-product review is necessary to determine whether the formula, labeling, claims, and other conditions fit the applicable pathway.
Related MOOYAM resources
- Cosmetics vs OTC Drugs in the United States
- US Cosmetic Ingredient Restrictions Explained
- MOOYAM OEM/ODM Cosmetics Manufacturing
Official sources
- FDA: How can I tell if my product is a cosmetic, a drug, or both?
- FDA: Cosmetics Labeling Claims
- FDA: Cosmetics Labeling Guide
- FDA: OTC Monograph M006—Topical Acne Drug Products
- FDA: MoCRA registration and listing information
Last reviewed: September 21, 2026. Regulatory requirements may change. Brands should verify current requirements with the relevant regulatory authority or a qualified compliance professional before placing products on the market.
Planning an anti-acne product? Contact MOOYAM to discuss an OEM/ODM project, the proposed claims, and the technical documentation needed for your target market.